<DOC>
	<DOCNO>NCT00577694</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , gemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving clofarabine together gemtuzumab may kill cancer cell . PURPOSE : This phase I trial study side effect best dose clofarabine give together gemtuzumab treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Clofarabine Gemtuzumab Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Identify maximum tolerate dose dose-limiting toxicity clofarabine administer gemtuzumab ozogamicin patient refractory acute myeloid leukemia ( AML ) AML relapse within 1 year cytarabine-containing therapy . Secondary - Estimate rate complete response and/or partial complete response incomplete platelet recovery patient treat regimen . - Estimate duration remission patient treat regimen proceed high-dose therapy allogeneic stem cell transplantation . - Estimate frequency patient enrol study proceed allogeneic autologous blood bone marrow stem cell transplantation . OUTLINE : This dose-escalation study clofarabine . Patients receive induction therapy comprise clofarabine IV day 1-5 gemtuzumab ozogamicin IV 2 hour day 1 , 4 , 7 course 1 . Beginning course 2 , blood count recover , patient receive consolidation therapy comprise clofarabine IV day 1-5 . Consolidation treatment repeat upon blood count recovery 2 course absence disease progression unacceptable toxicity . After completion study therapy , patient remission consolidation therapy follow monthly first 6 month , every 3-4 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) meet 1 follow criterion : Refractory disease , define persistent progressive disease ≥ 2 induction regimen , include ≥ 1 course highdose cytarabine ( ARAC ) Relapsed disease recur within 1 year ARACcontaining chemotherapy regimen No CNS disease require radiotherapy Patients neurological symptom must undergo lumbar puncture CT scan MRI brain exclude brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin ≤ 2.0 time upper limit normal ( ULN ) ALT AST ≤ 2.0 time ULN Serum creatinine ≤ 1.0 mg/dL OR glomerular filtration rate &gt; 60 mL/min INR ≤ 1.5 aPTT within ULN Patients receive anticoagulation therapy ( e.g. , warfarin heparin ) eligible provide anticoagulation therapy discontinue changed parenteral medication platelet count le 50,000/mm³ Negative pregnancy test Fertile patient must use effective contraception No concurrent active second primary malignancy ( exclude superficial , noninvasive skin cancer ) No active bleeding diathesis , include closely monitor therapeutic anticoagulation No cardiac disease , include follow : New York Heart Association class IIIV congestive heart failure Unstable angina ( i.e. , anginal symptom rest ) New onset angina ( i.e. , begin within past 3 month ) Myocardial infarction within past 6 month No active clinically serious infection &gt; grade 2 No cerebrovascular accident , include transient ischemic attack , within past 6 month No pulmonary hemorrhage ≥ grade 2 within past 4 week No hemorrhage bleed event ≥ grade 3 within past 4 week No know HIV infection chronic hepatitis B C No serious nonhealing wound ulcer More 4 week since prior significant traumatic injury No prior history sinusoidal obstructive syndrome ( venoocclusive disease ) PRIOR CONCURRENT THERAPY : More 4 week since prior major surgery open biopsy More 100 day since prior hematopoietic stem cell transplant No concurrent treatment investigational agent AML Intrathecal chemotherapy administration allow central nervous system leukemic infiltration No prior allogeneic stem cell transplant within past 100 day , active graftversushost disease ( GVHD ) grade , exposure immynosuppression GVHD prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>